News & Updates

In the phase II/III EPIC-HR* trial, the novel oral antiviral nirmatrelvir-ritonavir reduced the risk of progression of COVID-19 to severe disease, as well as viral load, in symptomatic, high-risk, unvaccinated nonhospitalized adults confirmed to have SARS-CoV-2 infection.

Among patients who suffer from disorders of consciousness (DoC) after severe COVID-19, around 10 percent can achieve functional independence after 1 year, reports a study presented at the recently concluded 2022 Annual Meeting of the American Academy of Neurology (AAN 2022).

An annual influenza vaccination does not lower the risk of cardiovascular (CV) outcomes in patients with heart failure (HF), though it may reduce the risk of pneumonia and hospitalization, according to results of the IVVE study presented at ACC.22.

The mRNA-1237 vaccine against the coronavirus disease 2019 (COVID-19) retains good immunogenicity in patients with mild antibody deficiencies and phagocyte defects, reports a recent study.

Prolonged corrected QT interval (QTc), as determined via electrocardiogram (ECG), may indicate an elevated risk of myocardial injury and death in patients hospitalized for COVID-19, according to a prospective study from Israel presented at EHRA 2022.

Patients who have had to delay their intravenous thrombolysis (IVT) procedures due to the COVID-19 pandemic suffer from worse short-term clinical outcomes such as higher rates of mortality and hospice care, reports a study presented at the Annual Meeting of the American Academy of Neurology (AAN 2022). These patients are also less likely to be discharged to their homes or to rehabilitation facilities.

A recent Mendelian randomization study has found sparse evidence supporting the association of circulating vitamin C levels with the coronavirus disease 2019 (COVID-19) or pneumonia.